Upadacitinib induction is effective and safe in ulcerative colitis patients including those with prior exposure to tofacitinib: a multicenter real-world cohort study

Upadacitinib resulted in high rates of clinical remission at 8 and 16 weeks in this large real-world cohort of ulcerative colitis patients. Upadacitinib is effective in patients with prior tofacitinib exposure. Intestinal ultrasound shows significant rates of transmural remission at week 8, sustained through week 16.

Authors

Institutions

Publication Details

Journal
Intestinal Research
Published
2024-12-22
DOI
https://doi.org/10.5217/ir.2024.00127
Citations
11
Primary Topic
Inflammatory Bowel Disease
Type
article
Field-Weighted Citation Impact
6.05
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Upadacitinib induction is effective and safe in ulcerative colitis patients including those with prior exposure to tofacitinib: a multicenter real-world cohort study

Robert Venning Bryant, Daniel Lightowler, Rupert W. Leong, Imogen Hartley et al.
11 citations
Intestinal Research
Inflammatory Bowel Disease
6.05
article

Upadacitinib induction is effective and safe in ulcerative colitis patients including those with prior exposure to tofacitinib: a multicenter real-world cohort study

Robert Venning Bryant, Daniel Lightowler, Rupert W. Leong, Imogen Hartley, Britt Christensen, Abhey Singh, Robert Gilmore, Abhinav Vasudevan, Steven Kim, Jakob Begun, Mahy M. Mona, Bridgette Andrew, Nik S. Ding, Yoon‐Kyo An, Richard Fernandes, Gregory Moore, Jonathan Segal, Jack West, Tessa Greeve, Aditya Mithanthaya, Sangwoo Han, Crispin Corte, Kannan Venugopaul, Arteen Arzivian
article en
11 citations

Abstract

Upadacitinib resulted in high rates of clinical remission at 8 and 16 weeks in this large real-world cohort of ulcerative colitis patients. Upadacitinib is effective in patients with prior tofacitinib exposure. Intestinal ultrasound shows significant rates of transmural remission at week 8, sustained through week 16.

Intestinal ResearchVol. 23(3)
The University of Sydney (AU), The Royal Melbourne Hospital (AU), The University of Queensland (AU), The University of Melbourne (AU), The University of Western Australia (AU), Royal Prince Alfred Hospital (AU), Royal Perth Hospital (AU), Townsville Hospital (AU), Fiona Stanley Hospital (AU), Wexford General Hospital (IE), St Vincent's Hospital Melbourne (AU), Mater Research (AU), Eastern Health (AU), Queen Elizabeth Hospital (AU), Monash Health (AU), Mater Adult Hospital (AU), Monash University (AU), Macquarie University (AU)
Zero hunger
Openalex Percentile: Top 3%
Inflammatory Bowel Disease
6.05
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.